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Introduction
In patients undergoing elective surgery, bag/facemask ventilation is generally performed after the induction of anaesthesia for pre-oxygenation. However, when an endotracheal rapid sequence intubation (RSI) for emergency surgery is needed, options for pre- and re-oxygenation are limited because of the risk of gastric insufflation leading to increased intra-gastric 
pressure and raised risk of pulmonary aspiration using standard bag/facemask ventilation (1-4).
Indeed, patients undergoing RSI may benefit from pre-oxygenation to increase the oxygen reservoir in the lungs to reduce 
intubation-related oxyhaemoglobin desaturation (5). Thus far, optimal pre-oxygenation has usually been performed using 
oxygen at an inspiratory oxygen fraction (FiO2) of 1 using a facemask, which allows the extension of time for intubation up 
to 6 min (5, 6). Humidified nasal cannula high-flow oxygen therapy (HFNO) utilises an air oxygen blend heated and hu-
midified through an active heated humidifier and delivered to the patient via a single limb heated inspiratory circuit (to avoid 
heat loss and condensation) using large-diameter nasal prongs (7). It allows FiO2 delivery from 21% to 100% and generates 
up to 60 L.min−1 flow rates (8). Theoretically, HFNO offers significant advantages over conventional oxygen in oxygenation 
and ventilation. Constant high-flow oxygen delivery provides steady FiO2 and decreases oxygen dilution (9). It washes out 
physiologic dead spaces and generates positive end expiration pressure that augments the functional residual capacity (FRC) 
and improves ventilation (10, 11). Heated humidification also facilitates secretion clearance, decreases bronchospasm and 
Objective: To assess the efficacy and safety of high-flow nasal oxygen (HFNO) therapy in patients undergoing rapid sequence intubation 
(RSI) for emergency abdominal surgery.
Methods: HFNO of 60 L.min−1 at an inspiratory oxygen fraction of 1 was delivered 4 min before laryngoscopy and maintained until the 
patient was intubated, and correct intubation was verified by the appearance of the end-tidal CO2 (EtCO2) waveform. Transcutaneous 
oxygenation (SpO2), heart rate and non-invasive mean arterial pressure were monitored at baseline (T0), after 4 min on HFNO (T1) and 
at the time of laryngoscopy (T2) and endotracheal intubation (ETI) (T3). An SpO2 of <3% from baseline was recorded at any sampled 
time. The value of EtCO2 at T3 was registered after two mechanical breaths. The apnoea time was defined as the time from the end of 
propofol injection to ETI. RSI was performed with propofol, fentanyl and rocuronium.
Results: Forty-five patients were enrolled. SpO2 levels showed a statistically significant increase at T1, T2 and T3 compared with those 
at T0 (p<0.05); median SpO2% (interquartile range) was 97% (range, 96%-99%) at T0, 99% (range, 99%-100%) at T1, 99% (range, 
99%-100%) at T2 and 99% (range, 99%-100%) at T3. Minimal SpO2 was 96%; no patient showed an SpO2 of <3% from baseline; mean 
EtCO2 at the time of ETI was 36±4 mmHg. Maximum apnoea time was 12 min.
Conclusion: HFNO is an effective and safe technique for pre-oxygenation in patients undergoing rapid sequence induction of general 
anaesthesia for emergency surgery.
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maintains mucosal integrity (8). Although HFNO has been 
used in several clinical fields, only few studies (12-14) have 
used HFNO as transnasal humidified rapid-insufflation ven-
tilatory exchange (THRIVE) at 70 L min−1 to prolong the ap-
noea time in anaesthetised and paralysed patients. Therefore, 
we designed an efficacy and safety study on the use of HFNO 
during RSI by monitoring the oxygenation status and inci-
dence of unwanted events.
Methods
This was a single-centre, observational, feasibility and safety 
study performed at the Policlinico Paolo Giaccone, Universi-
ty of Palermo, Italy, between September 2016 and June 2017. 
The ethics committee ‘Comitato Etico Palermo 1’ approved 
the study protocol. Patients aged >18 years who required RSI 
in general anaesthesia for urgent/emergency abdominal surgery 
and who were competent to give informed consent were re-
cruited. Patients were excluded if they were aged <18 years; 
pregnant at any gestational time; affected by acute coronary 
syndrome or significant cardiovascular disease; had obstructive 
sleep apnoea syndrome (OSAS) with or without ventilator 
support with oro-tracheal or rapid-induction contraindica-
tions or unable to give informed consent. Informed consent 
was obtained from patients in the surgical ward or emergency 
department on the day of the surgery. All patients were subject-
ed to modified RSI in which pre-oxygenation was performed 
with HFNO (Optiflow, Fisher & Paykel, New Zealand) for 4 
min with a flow rate of 60 L.min−1 at FiO2 1, and patients were 
instructed to keep the mouth closed. HFNO was continued 
until the endotracheal tube was secured. General anaesthesia 
was induced with a titrated dose of propofol (2.5 mg kg-1), fen-
tanyl (3 µg kg-1) and rocuronium (1.2 mg kg-1). After allowing 
1 min for the rocuronium to provide an effective neuromuscu-
lar block, laryngoscopy was performed. All patients continued 
to receive HFNO during laryngoscopy until correct intubation 
was verified by the end-tidal CO2 (EtCO2) waveform. Periph-
eral oxygen saturation (SpO2), heart rate (HR) and non-inva-
sive mean arterial pressure (nMAP) were measured at baseline 
(T0), after 4 min on HFNO (T1) and at the time of laryn-
goscopy (T2) and endotracheal intubation (ETI) (T3). SpO2 
and HR were monitored using a pulse oxymeter (PM100N 
Nellcor™, Medtronic, USA), and EtCO2 was detected using 
the Ultracare SLP 100 Anesthesia Monitor (SPACELABs 
Healthcare, USA). An SpO2 of <3% from baseline was record-
ed at any sampled time. EtCO2 at T3 was registered after two 
mechanical breaths. The apnoea time was defined as the time 
from the end of induction agent injection to ETI. The primary 
outcome was SpO2 and its modification at the four time points 
(T0–T3).
An investigator not involved in the anaesthetic management 
recorded the pre-oxygenation time and collected the parame-
ters of interest. Information regarding patient characteristics 
and comorbidity, type of surgical intervention (grade of ur-
gency and type of surgery), modified Mallampati score, in-
ter-incisive distance, planned airway difficulty management 
and STOP-BANG (15) were recorded. The number of at-
tempts and total duration of laryngoscopy, Cormack–Lehane 
laryngoscopy grade and use of any rescue manoeuvre were 
also recorded. The presence or absence of adverse events (se-
vere desaturation<80%, hemodynamic instability [defined as 
MAP<60 mmHg with a need for vasoactive agents, cardiac 
arrhythmias and cardiac arrest], vomits with aspiration of 
gastric content and intubation failure) was reported.
Statistical analysis
Data are presented as mean±standard deviation (SD). 
Non-normally distributed variables are expressed as medi-
an±interquartile range (IQR). Data distribution was evalu-
ated using the Kolmogorov–Smirnov test; ANOVA test was 
used to compare a series of repeated measurements. When 
the data distribution was not normal, Friedman test was used. 
Statistical analysis was performed using MedCalc (MedCalc 
Software, Ostend, Belgium). A p (two tails) value of <0.05 
was considered significant.
Results
During the study period, 49 patients were screened, of which 
four were excluded because of OSAS (three patients) and a 
lack of informed consent (one patient). Characteristics (an-
thropometric data, comorbidities, type of surgery, pre-opera-
tive and intra-operative airway evaluation) of the 45 patients 
are shown in Table 1. SpO2, HR and MAP at any sampled 
time are shown in Table 2. Apnoea times are shown in Ta-
ble 3. Minimal SpO2 was 96%; no patient showed an SpO2 
of <3% from baseline. SpO2 levels showed a statistically sig-
nificant increase at T1, T2 and T3 compared with those at 
T0 (p<0.05); median SpO2% (IQR) was 97% (range, 96%–
99%) at T0, 99% (range, 99%–100%) at T1, 99% (range, 
99%–100%) at T2 and 99% (range, 99%–100%) at T3. The 
mean EtCO2 at T3 was 36.2 mmHg (SD, 4.2). Unexpect-
ed difficult intubation was observed in seven patients, but 
no airway rescue manoeuvres were needed in any patient. In 
one patient, the maximum apnoea time was 12 min because 
of three intubation attempts; the haemodynamic profile was 
stable throughout the procedure. SpO2 at T0–T3 was 95%, 
99%, 96% and 98%, respectively. EtCO2 at the time of intu-
bation was 44 mmHg.
Discussion
This study aimed to assess the efficacy and safety of using 
HFNO as a pre-oxygenation method in patients undergoing 
RSI. The main outcome was that with the use of HFNO, the 
minimal SpO2 was 96%. In addition, no patient showed an 
SpO2 of <3% from baseline, while the mean EtCO2 at the 
time of ETI was 36±4 mmHg.
Our results are in contrast with those of Ang et al. (16) who 
recently demonstrated that the Optiflow system rapidly in-
creases EtO2, but the variability in the extent of de-nitroge-
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nation suggests that it is not a reliable alternative to facemask 
ventilation in pre-oxygenating patients. However, our results 
are in agreement with those of Mir et al. (12) who demon-
strated that THRIVE is a practicable method for pre-oxygen-
ating patients during RSI.
We used a continuous flow at 60 L min−1 instead of 70 L 
min−1 as performed by Mir et al. (12). It has been demon-
strated that at 60 L min−1, with the mouth closed, an HFNO 
was effective as 3 min oxygen by facemask at 10 L min−1 (17). 
At 70 L min−1, the median (IQR [range]) EtO2 at 180 s of 
pre-oxygenation was 86% (84–90 [78–92]) (16). Finally, yet 
importantly, in our study, the oxygen flow rate was started at 
60 L min−1 from the beginning of pre-oxygenation. Mir et al. 
(12) started HFNO at 30 L min−1, and the flow was increased 
to 70 L min−1 over the course of the first minute of pre-ox-
ygenation. A lower flow rate could also theoretically affect 
the carbon dioxide washout (18). Nevertheless, our EtCO2 
values were not higher than their PaCO2 values obtained after 
intubation.
Interestingly, one patient had an apnoea time of 720 s. Patel 
et al. (13) have shown that in patients with known or an-
ticipated difficult airways, oxygenation using the THRIVE 
technique is associated with prolonged apnoea time before 
arterial oxygen desaturation. The median (IQR [range]) ap-
noea time was 14 min (9-19 [5-65]). No patient experienced 
arterial desaturation of <90%. As explained by Mir et al. (12), 
this fact may be related to both effective supply of oxygen and 
other mechanisms, such as apnoeic ventilation (19-21). In 
addition, during pre-oxygenation with HFNO, end expirato-
ry lung volume and FRC increased and dead space decreased 
(18, 22-25).
It can be argued that EtCO2 values do not reflect actual al-
veolar carbon dioxide values (12). However, only 33% of pa-
tients were affected by chronic respiratory diseases (26). In 
addition, although pH was not measured, EtCO2 values in 
Table 1. Patients’ characteristics and information on 
anaesthesia induction
 n=45
Age, years (mean, SD) 57 (18.1)
Sex, male (%) 22 (48)
BMI, kg m-2 (mean, SD) 26.5 (4.3)
ASA physical status (%) 
1 1 (2)
2 15 (33)
3 27 (60)
4 2 (4)
Comorbidities (%) 
Cardiovascular 24 (53)
Respiratory 15 (33)
Gastrointestinal 18 (40)
Metabolic 16 (35)
Renal 3 (6)
Type of surgery (%) 
Upper abdomen 15 (33)
Lower abdomen 30 (67) 
STOP-BANG>5 (%) 1 (2)
Cormack–Lehane grade (%) 
1 11 (24)
2 27 (60)
3 7 (16)
Modified Mallampati score (%) 
1 9 (20)
2 26 (58)
3 10 (22)
Inter-incisor gap<3 cm (%) 8 (18)
Tyromental distance<6 cm (%) 5 (11)
Grade of intubator; Trainee (%) 35 (78)
Number of attempts at laryngoscopy (%) 
<2 38 (84)
>2 7 (16)
ASA: American Society of Anesthesiology; STOP-BANG: Snoring, Tired, 
Observed, Pressure, Body Mass Index, Age, Neck Size, Gender; BMI: body 
mass index; SD: standard deviation
Table 2. SpO2, HR and MAP at any sampled time
 SpO2  HR MAP EtCO2 
Time median (IQR) (mean, SD) (mean, SD) (mean, SD)
T0 97 (96-99)* 75 (14.3) 103 (12.4) -
T1 99 (99-100) 77 (16.2) 97 (14.4) -
T2 99 (99-100) 78 (16.2) 94 (16.7)  -
T3 99 (99-100) 79 (16.1) 83 (15.8) 36.4 (4.2)
*SpO2 levels showed statistically significant increase at T1, T2 and T3 
compared with that at baseline (T0); IQR: interquartile range; SD: standard 
deviation; SpO2: transcutaneous oxygenation; HR: heart rate; MAP: mean 
arterial pressure; EtCO2: end-tidal carbon dioxide
Table 3. Apnoea time during the procedure
Apnoea time (minute range) Number of patients (%)
1–3 29 (64)
3–6 9 (20)
6–9 6 (13)
9–12 1 (2)
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the present study were far from those causing severe respira-
tory acidosis as was shown using THRIVE in patients under 
apnoeic oxygenation for laryngeal surgery (27).
We found a stable haemodynamic profile in our patients 
during RSI. It can be speculated that HFNO maintaining 
suitable arterial blood gases led to good haemodynamic sta-
bility.
The present study has several limitations: (1) We did not 
measure EtO2. The efficacy of pre-oxygenation is dependent 
on the inspired O2 concentration, duration of pre-oxygen-
ation, alveolar ventilation and FRC and EtO2 (16, 17). It has 
been argued that pre-oxygenation can be claimed to be effec-
tive only if fractional EtO2 of >90% is achieved. However, 
measuring EtO2 may have methodological issues (12, 16, 17, 
28), and the concept of pre-oxygenation is not related only 
to a fractional ETO2 of >90%. Measurements of pre-oxygen-
ation have focused on EtO2 of >90% because this is the most 
readily measurable, whereas a more accurate measure of the 
efficacy of pre-oxygenation is the arterial oxygen partial pres-
sure. Although transcutaneous oxygen (PtO2) was monitored 
in our study (14), SpO2 assessment has been found to be at 
least more favourable than PtO2 as a non-invasive method 
to analyse blood oxygenation (14). Additionally, we can say 
that SpO2 is more important than PaO2 regarding the effect 
on oxygen delivery to tissues (14). Mir et al. (12) did not 
report any systematic SpO2 value during the procedure. We 
speculate that SpO2 assessment shows benefits compared with 
the analysis of multiple arterial sampling (14), which would 
not be realistic in the context of RSI. (2) The study was not 
randomised as opposed to facemask oxygenation performed 
by Mir et al. (12). In fact, our results do not indicate the 
superiority or inferiority of HFNO over conventional modes 
of pre-oxygenation. Although we acknowledge this fact, our 
ethical committee, at the time when the study was designed, 
did not approve a randomised controlled trial unless an antic-
ipated efficacy and safety study was conducted.
Conclusion
High-flow oxygen therapy seems to be safe and effective for 
pre-oxygenation and for maintaining oxygenation in patients 
receiving RSI for urgent/emergency abdominal surgery. Fu-
ture randomised trials are needed to assess the range of ap-
noea time in different patient populations (12).
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